Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Howard Levy, MD, PhD, MMM
Sponsor GmbH
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medical Center "hippocrates - N"
Plovdiv, Bulgaria
- Specialized Hospital for Active Treatment of Hematological Diseases
Sofia, Bulgaria
- Kirov Research Institute of Hematology and Blood Transfusion
Kirov, Russia
- National Medical Hematology Research Center
Moscow, Russia
- Municipal Policlinic # 37, City Center for Hemophilia Treatment
Saint Petersburg, Russia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Sept 2019
- Primary completion
- 30 Apr 2020
- Completion
- 17 Jun 2020
- Last update posted
- 13 Sept 2021
- Registered enrollment
- 11
- Registry id
- NCT04072237
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.